Tests CAR-T cell therapy in people with lupus
Tests CAR-T cell therapy for safety in adults with lupus.
Plain-language title generated from the registry record
Registry title: A Study of CAR-T Cells in Subjects With Systemic Lupus Erythematosus
Key facts
- Where
- Wuhan, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06900764, who can take part
Where in China
- Wuhan Union HospitalWuhan, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Trial code
- NCT06900764
- Record updated
- 17 July 2025
- Original description
The purpose of this study is to assess the safety and efficacy of CAR-T cell therapy in Subjects with SLE.Read full original descriptionShow less
A Study to Evaluate the Safety and Efficacy of CAR-T Cells in Subjects With Systemic Lupus Erythematosus (SLE)
The purpose of this study is to assess the safety and efficacy of CAR-T cell therapy in Subjects with SLE.
Inclusion: Male or female, between 18 and 65 years old; Diagnosed with SLE according to 2019 EULAR/ACR SLE classifications; Positivity for ANA (titer≥1:80), and/or anti-dsDNA, and/or anti-Smith antibody at screening; SLEDAI-2K≥8 points (with a clinical SLEDAI-2K≥6 points) ; Patients who have used stable standard treatment regimen for at least 6 months in their medical history before screening, and their condition is still active for at least 2 months before screening; Good organ functions; Voluntary participates this trial and can comprehend and sign ICF.
Exclusion: Had been subjected to treatment by CD19 targeted therapy or CAR-T therapy or any gene therapy; Had or has active malignancy; Combined with other autoimmune disease that needs treatment; Pregnant or lactating women; Has other factors that deemed not suitable by investigator.